PortalPublikationenImproving Lentiviral Transduction of CD34(+) Hematopoietic S...

Improving Lentiviral Transduction of CD34(+) Hematopoietic Stem and Progenitor Cells

Standard

Improving Lentiviral Transduction of CD34(+) Hematopoietic Stem and Progenitor Cells. / Hauber, Ilona; Beschorner, Niklas; Schrödel, Silke; Chemnitz, Jan; Kröger, Nicolaus; Hauber, Joachim; Thirion, Christian.

in: HUM GENE THER METHOD, Jahrgang 29, Nr. 2, 04.2018, S. 104-113.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hauber, I, Beschorner, N, Schrödel, S, Chemnitz, J, Kröger, N, Hauber, J & Thirion, C 2018, 'Improving Lentiviral Transduction of CD34(+) Hematopoietic Stem and Progenitor Cells', HUM GENE THER METHOD, Jg. 29, Nr. 2, S. 104-113. https://doi.org/10.1089/hgtb.2017.085

APA

Hauber, I., Beschorner, N., Schrödel, S., Chemnitz, J., Kröger, N., Hauber, J., & Thirion, C. (2018). Improving Lentiviral Transduction of CD34(+) Hematopoietic Stem and Progenitor Cells. HUM GENE THER METHOD, 29(2), 104-113. https://doi.org/10.1089/hgtb.2017.085

Vancouver

Hauber I, Beschorner N, Schrödel S, Chemnitz J, Kröger N, Hauber J et al. Improving Lentiviral Transduction of CD34(+) Hematopoietic Stem and Progenitor Cells. HUM GENE THER METHOD. 2018 Apr;29(2):104-113. https://doi.org/10.1089/hgtb.2017.085

Bibtex

@article{8162a3729ff848fb9672410a457fea10,
title = "Improving Lentiviral Transduction of CD34(+) Hematopoietic Stem and Progenitor Cells",
abstract = "The delivery of therapeutic genes for treatment of inherited or infectious diseases frequently requires lentiviral transduction of CD34+ hematopoietic stem and progenitor cells (HSC). Optimized transduction protocols with a therapeutic goal aim to maximize the number of transduction-positive cells while limiting the vector copy number that reach each individual cell. Importantly, the transduced HSC should maintain their {"}stem-like{"} properties. Here, we analyzed LentiBOOST{\texttrademark} reagent, a membrane-sealing poloxamer, with respect to enhancing lentiviral transduction of CD34+ peripheral blood stem cells. We demonstrate that inclusion of LentiBOOST{\texttrademark} in a standard HSC transduction protocol yields high transduction efficiencies while preserving the ability of the transduced HSC to differentiate into various hematopoietic lineages. Thus, LentiBOOST{\texttrademark} reagent can significantly improve lentiviral CD34+ HSC transduction protocols with the potential to improve production of gene-modified cell products.",
keywords = "Journal Article",
author = "Ilona Hauber and Niklas Beschorner and Silke Schr{\"o}del and Jan Chemnitz and Nicolaus Kr{\"o}ger and Joachim Hauber and Christian Thirion",
year = "2018",
month = apr,
doi = "10.1089/hgtb.2017.085",
language = "English",
volume = "29",
pages = "104--113",
journal = "HUM GENE THER METHOD",
issn = "1946-6536",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Improving Lentiviral Transduction of CD34(+) Hematopoietic Stem and Progenitor Cells

AU - Hauber, Ilona

AU - Beschorner, Niklas

AU - Schrödel, Silke

AU - Chemnitz, Jan

AU - Kröger, Nicolaus

AU - Hauber, Joachim

AU - Thirion, Christian

PY - 2018/4

Y1 - 2018/4

N2 - The delivery of therapeutic genes for treatment of inherited or infectious diseases frequently requires lentiviral transduction of CD34+ hematopoietic stem and progenitor cells (HSC). Optimized transduction protocols with a therapeutic goal aim to maximize the number of transduction-positive cells while limiting the vector copy number that reach each individual cell. Importantly, the transduced HSC should maintain their "stem-like" properties. Here, we analyzed LentiBOOST™ reagent, a membrane-sealing poloxamer, with respect to enhancing lentiviral transduction of CD34+ peripheral blood stem cells. We demonstrate that inclusion of LentiBOOST™ in a standard HSC transduction protocol yields high transduction efficiencies while preserving the ability of the transduced HSC to differentiate into various hematopoietic lineages. Thus, LentiBOOST™ reagent can significantly improve lentiviral CD34+ HSC transduction protocols with the potential to improve production of gene-modified cell products.

AB - The delivery of therapeutic genes for treatment of inherited or infectious diseases frequently requires lentiviral transduction of CD34+ hematopoietic stem and progenitor cells (HSC). Optimized transduction protocols with a therapeutic goal aim to maximize the number of transduction-positive cells while limiting the vector copy number that reach each individual cell. Importantly, the transduced HSC should maintain their "stem-like" properties. Here, we analyzed LentiBOOST™ reagent, a membrane-sealing poloxamer, with respect to enhancing lentiviral transduction of CD34+ peripheral blood stem cells. We demonstrate that inclusion of LentiBOOST™ in a standard HSC transduction protocol yields high transduction efficiencies while preserving the ability of the transduced HSC to differentiate into various hematopoietic lineages. Thus, LentiBOOST™ reagent can significantly improve lentiviral CD34+ HSC transduction protocols with the potential to improve production of gene-modified cell products.

KW - Journal Article

U2 - 10.1089/hgtb.2017.085

DO - 10.1089/hgtb.2017.085

M3 - SCORING: Journal article

C2 - 29631437

VL - 29

SP - 104

EP - 113

JO - HUM GENE THER METHOD

JF - HUM GENE THER METHOD

SN - 1946-6536

IS - 2

ER -